[go: up one dir, main page]

CL2008003085A1 - Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales. - Google Patents

Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.

Info

Publication number
CL2008003085A1
CL2008003085A1 CL2008003085A CL2008003085A CL2008003085A1 CL 2008003085 A1 CL2008003085 A1 CL 2008003085A1 CL 2008003085 A CL2008003085 A CL 2008003085A CL 2008003085 A CL2008003085 A CL 2008003085A CL 2008003085 A1 CL2008003085 A1 CL 2008003085A1
Authority
CL
Chile
Prior art keywords
tetrazol
psychiatric
triazol
neurological
modulators
Prior art date
Application number
CL2008003085A
Other languages
English (en)
Inventor
Methvin Isaac
Louise Edwards
Erwan Arzel
Abdelmalik Slassi
Donald A Mcleod
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008003085A1 publication Critical patent/CL2008003085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos derivados de 4-metil-5-[1-(2-fenil-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il, moduladores del receptor mglur5; composición farmacéutica que comprende dichos compuestos; y uso para un desorden neurológico, siquiátrico o gastrointestinal como dispepsia, Alzheimer, Parkinson, depresión, ansiedad, entre otros.
CL2008003085A 2007-10-19 2008-10-17 Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales. CL2008003085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98129407P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CL2008003085A1 true CL2008003085A1 (es) 2009-10-09

Family

ID=40567640

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003085A CL2008003085A1 (es) 2007-10-19 2008-10-17 Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.

Country Status (21)

Country Link
US (1) US7960422B2 (es)
EP (1) EP2231647A4 (es)
JP (1) JP2011500673A (es)
KR (1) KR20100090777A (es)
CN (1) CN101896480A (es)
AR (1) AR068921A1 (es)
AU (1) AU2008312055A1 (es)
BR (1) BRPI0818448A2 (es)
CA (1) CA2703425A1 (es)
CL (1) CL2008003085A1 (es)
CO (1) CO6321281A2 (es)
CR (1) CR11376A (es)
DO (1) DOP2010000119A (es)
EA (1) EA201000654A1 (es)
IL (1) IL204958A0 (es)
MX (1) MX2010004272A (es)
PE (1) PE20090875A1 (es)
TW (1) TW200934771A (es)
UY (1) UY31403A1 (es)
WO (1) WO2009051556A1 (es)
ZA (1) ZA201002694B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
US8754073B2 (en) 2007-10-19 2014-06-17 Boehringer Ingelheim International Gmbh Substituted piperazino-dihydrothienopyrimidines
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
KR20130105914A (ko) 2008-09-22 2013-09-26 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
CN102256967A (zh) * 2008-12-18 2011-11-23 阿斯利康(瑞典)有限公司 制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法
EP2438052A1 (en) * 2009-06-05 2012-04-11 Oslo University Hospital HF Azole derivatives as wtn pathway inhibitors
CA2820800A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
BR112013023813A2 (pt) 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN106032377A (zh) * 2015-03-12 2016-10-19 天津药物研究院有限公司 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663332A (en) * 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
WO1993002677A1 (en) 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
JP4303109B2 (ja) 2001-10-04 2009-07-29 メルク エンド カムパニー インコーポレーテッド 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤
EP1485093B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CA2494987C (en) * 2002-08-09 2012-04-17 Astrazeneca Ab Isoxazoles and their use as modulators of metabotropic glutamate receptor-5
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
CA2555272A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2372347C2 (ru) * 2004-02-18 2009-11-10 Астразенека Аб Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
TW200604183A (en) * 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200811156A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV

Also Published As

Publication number Publication date
KR20100090777A (ko) 2010-08-17
US7960422B2 (en) 2011-06-14
CN101896480A (zh) 2010-11-24
EA201000654A1 (ru) 2010-12-30
IL204958A0 (en) 2010-11-30
AR068921A1 (es) 2009-12-16
US20090131454A1 (en) 2009-05-21
WO2009051556A1 (en) 2009-04-23
CR11376A (es) 2010-07-19
AU2008312055A1 (en) 2009-04-23
UY31403A1 (es) 2009-05-29
BRPI0818448A2 (pt) 2015-05-12
DOP2010000119A (es) 2010-05-31
PE20090875A1 (es) 2009-08-08
ZA201002694B (en) 2011-03-30
CO6321281A2 (es) 2011-09-20
EP2231647A4 (en) 2011-08-31
EP2231647A1 (en) 2010-09-29
MX2010004272A (es) 2010-04-30
JP2011500673A (ja) 2011-01-06
CA2703425A1 (en) 2009-04-23
TW200934771A (en) 2009-08-16

Similar Documents

Publication Publication Date Title
CL2008003085A1 (es) Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CL2011003085A1 (es) Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes.
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
CL2007002595A1 (es) Compuestos derivados de n-(1-hetaril-piperidin-4-il)-(het)arilamida, moduladores del receptor ep2; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de la fertilidad, trastornos menstruale
CY1113734T1 (el) Χημικες ενωσεις
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2011000662A1 (es) Compuestos derivados de n-heteroaril-sulfonil-amida, moduladores selectivos del receptor cb2; composicion farmaceutica; y uso para el tratamiento del dolor, enfermedad pulmonar,enfermedad autoinmune, enfermedad neurologica, entre otras.
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
HN2010002772A (es) Compuestos organicos nuevo titulo de la invencion: derivados de 2-(3-piridil)-indol sustituido y composicionesfarmaceuticas de los mismos. (bajo el escrito 2013-000513 de fecha 27 de febrero de 2013) solicitado por esta oficina de registro
MX2009012755A (es) Imidazoles 1,(3,)5-substituidos, su uso en el tratamiento de hipertension y metodos para su preparacion.
CL2009000256A1 (es) Imidazolinas fenil sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, sindrome de stein-leventhal, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y dependencia a la nicotina.
CL2008002506A1 (es) Compuestos derivados de bencimidazol sustituido, procedimiento de preparacion, composicion farmaceutica, util en el tratamiento de enfermedades moduladas con antagonistas del receptor fxr, en particular para el tratamiento de los niveles incrementados de lipidos y/o colesterol, enfermedad aterosclerotica, diabetes, cancer, parkinson, alzheimer.
CL2007000396A1 (es) Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos.
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
DOP2006000219A (es) Indoles de acilo, composiciones que contienen dichos compuestos y procedimientos de uso
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida